The potential of CX3CL1 in the pathogenesis of fibrosing lung disease development was shown to be valid regardless of the origin of fibrosis—be it a primary (IPF) or secondary fibrotic process (HP, CTD-ILD, PS). Here, CX3CL1 is linked to interstitial lung disease.